| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ea3708b29221afdb98dc3b6e22e80490 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-95
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-31 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-435
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-435
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate |
2016-02-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_564aeb475ac55fdbd06dce176715af08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_73d899e68c4a69a6b9d3db7176b6dc28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7c7b5a00f51dc57c9936d24eda881bbf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3a5841b1810bd8ce28fb54c9b14979df |
| publicationDate |
2018-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2018030098-A1 |
| titleOfInvention |
Novel egfr binding proteins |
| abstract |
The present invention relates to new EGFR binding molecules based on ubiquitin muteins (Affilin®), preferably Affilin molecules having a characteristic three amino acid residue motif. The invention further refers to EGFR binding molecules that bind to different or non-overlapping epitopes than the anti-EGFR monoclonal antibody Cetuximab. The invention further relates to the use of these EGFR binding proteins in medicine, preferably for use in the diagnosis or treatment of cancer. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11414466-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023285164-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10808042-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10584152-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2021340237-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11230576-B2 |
| priorityDate |
2015-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |